Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;16(4):831-841.
doi: 10.1007/s11739-021-02688-x. Epub 2021 Mar 13.

Diagnosis and management of leukocytoclastic vasculitis

Affiliations
Review

Diagnosis and management of leukocytoclastic vasculitis

Paolo Fraticelli et al. Intern Emerg Med. 2021 Jun.

Abstract

Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small vessel vasculitis (SVV), that can be found in various types of vasculitis affecting the skin and internal organs. The leading clinical presentation of LCV is palpable purpura and the diagnosis relies on histopathological examination, in which the inflammatory infiltrate is composed of neutrophils with fibrinoid necrosis and disintegration of nuclei into fragments ("leukocytoclasia"). Several medications can cause LCV, as well as infections, or malignancy. Among systemic diseases, the most frequently associated with LCV are ANCA-associated vasculitides, connective tissue diseases, cryoglobulinemic vasculitis, IgA vasculitis (formerly known as Henoch-Schonlein purpura) and hypocomplementemic urticarial vasculitis (HUV). When LCV is suspected, an extensive workout is usually necessary to determine whether the process is skin-limited, or expression of a systemic vasculitis or disease. A comprehensive history and detailed physical examination must be performed; platelet count, renal function and urinalysis, serological tests for hepatitis B and C viruses, autoantibodies (anti-nuclear antibodies and anti-neutrophil cytoplasmic antibodies), complement fractions and IgA staining in biopsy specimens are part of the usual workout of LCV. The treatment is mainly focused on symptom management, based on rest (avoiding standing or walking), low dose corticosteroids, colchicine or different unproven therapies, if skin-limited. When a medication is the cause, the prognosis is favorable and the discontinuation of the culprit drug is usually resolutive. Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.

Keywords: Cryoglobulinemic vasculitis; Hypocomplementemic urticarial vasculitis; IgA vasculitis; Leukocytoclastic vasculitis; Small vessel vasculitis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Clinical presentation of LCV. Most frequent cutaneous lesions are petechiae (panel A), purpura (panel B), confluent purpura (panel C), urticarial wheals (panel D), bullous-hemorrhagic purpura (panel E) and deep-skin ulcers and nodules (panel F)
Fig. 2
Fig. 2
Diagnostic algorithm of leukocytoclastic vasculitis Abbreviations WBC white blood cells, Hct hematocrit, Hgb hemoglobin, CT computed tomography. ANCA anti-neutrophil cytoplasmic antibodies; ANA antinuclear antibodies; ENA extractable nuclear antibodies
Fig. 3
Fig. 3
Histopathological findings in LCV. Skin biopsy with evident perivascular neutrophilic infiltrate in the dermis with fibrinoid deposits (arrow) (a). Fibrinoid necrosis (arrow) of deep large arterioles in the subdermal fat panniculus (b). Eosinophils rich mixed to neutrophilic perivascular infiltrate (arrowhead) of an urticarial vasculitis (c). IFI staining for IgA deposits surrounding a cutaneous vessel (d)
Fig. 4
Fig. 4
Approach to the treatment of leukocytoclastic vasculitis The treatment of LCV depends on etiology and the extent of organ involvement. Abbreviations: CV cryoglobulinemic vasculitis, CTD connective tissue disease, AAV ANCA-associated vasculitis

References

    1. Caproni M, Verdelli A. An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol. 2019;31(1):46–52. - PubMed
    1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. - PubMed
    1. Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. 2018;70(2):171–184. - PubMed
    1. Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56(1):3–23. - PubMed
    1. Watts RA, Jolliffe VA, Grattan CEH, Elliott J, Lockwood M, Scott DGI. Cutaneous vasculitis in a defined population-Clinical and epidemiological associations. Vol. 25, Journal of Rheumatology. Department of Rheumatology, Ipswich Hospital, UK. FAU-Jolliffe, V A; 1998. p. 920–4. - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources